Travere Therapeutics Announces U.S. FDA Approves REMS Modification for Filspari (sparsentan) in IgA Nephropathy

Sep 1, 2025 - 23:00
 0  0
SAN DIEGO--(BUSINESS WIRE) August 27, 2025 -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has approved updated Risk Evaluation and Mitigation Strategy (REMS) labeling for Filspari®...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0